AJOVista LLC Takes $26,000 Position in Inhibrx, Inc. (NASDAQ:INBX)

AJOVista LLC purchased a new stake in Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 678 shares of the company’s stock, valued at approximately $26,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its position in shares of Inhibrx by 4,637.5% in the fourth quarter. Signaturefd LLC now owns 758 shares of the company’s stock worth $29,000 after buying an additional 742 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Inhibrx by 389.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,471 shares of the company’s stock valued at $208,000 after purchasing an additional 4,354 shares during the period. Arizona State Retirement System acquired a new position in shares of Inhibrx in the 4th quarter valued at about $209,000. Exchange Traded Concepts LLC lifted its position in shares of Inhibrx by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,705 shares of the company’s stock worth $255,000 after purchasing an additional 1,700 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Inhibrx during the third quarter worth approximately $232,000. 82.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on INBX. Lifesci Capital cut shares of Inhibrx from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 23rd. JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a research report on Tuesday, January 23rd.

Inhibrx Trading Up 0.4 %

Shares of INBX opened at $34.30 on Tuesday. The firm’s 50 day moving average price is $35.02 and its 200 day moving average price is $31.13. The company has a quick ratio of 5.25, a current ratio of 5.24 and a debt-to-equity ratio of 4.78. Inhibrx, Inc. has a twelve month low of $14.31 and a twelve month high of $39.79.

Inhibrx (NASDAQ:INBX) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.66). Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. The company had revenue of $1.63 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, equities research analysts forecast that Inhibrx, Inc. will post -4.34 EPS for the current year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.